Key result
Under 1% of eligible HFrEF patients achieve target triple-therapy doses over 12 months.
Why the study?
Guidelines recommend titration of medical therapy for HFrEF to target doses, but the degree to which titration occurs in contemporary US practice is unknown.
Observational (n=2,588)
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is the reality we live with in heart failure, without any meaningful outrage or accountability. Medical therapies that scaled a burden-of-proof barrier unprecedented in most disease states have invariably fallen flat in the implementation phase.”
“In the CHAMP-HF registry conducted in the United States, which included 2,588 patients with HFrEF who completed follow-up to 12 months, only 1.5% of patients were taking the stable target dose for 12 months.”
In contemporary US practice, the vast majority of eligible HFrEF patients do not achieve target doses of guideline-directed medical therapy over 12 months of follow-up, highlighting significant gaps in care optimization.
Background: Guidelines recommend titration of medical therapy for heart failure with reduced ejection fraction (HFrEF) to target doses derived from clinical trials, as tolerated. The degree to which titration occurs in contemporary United States (US) practice is unknown. Objectives: This study sought to characterize longitudinal titration of HFrEF medical therapy in clinical practice and identify associated factors and reasons for medication changes. Methods: Among 2,588 US outpatients with chronic HFrEF in the CHAMP-HF registry with complete medication data and no contraindications to medical therapy, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA) were examined at baseline and 12-month follow-up. Factors associated with medication changes were examined. Results: At baseline, 658 (25%), 525 (20%), 287 (11%), and 45 (2%) patients were receiving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI, respectively. At 12-months, proportions of patients with medication initiation/dosing increase were 6% for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresponding proportions with discontinuation/dosing decrease were 4%, 7%, 11%, and 3%. Over 12-months, <1% of patients were simultaneously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA. In multivariate analysis, across the classes of medication, multiple patient characteristics were associated with higher likelihood of initiation/dosing increase (e.g., prior HF hospitalization, higher blood pressure, lower ejection fraction) and discontinuation/dosing decrease (e.g., prior HF hospitalization, impaired quality of life, more severe functional class). Medical reasons were the most common underlying reasons for discontinuations and dosing decreases, but the contributions from patient preference, health team, and systems-based reasons varied by medication. Conclusions: In this contemporary US registry, the large majority of eligible HFrEF patients did not receive target doses of medical therapy at any point during follow-up and few patients had doses increased over time. Although most patients had no alterations in medical therapy, multiple clinical factors were independently associated with medication changes. Further quality improvement efforts are urgently needed to improve guideline-directed medication titration.
No takes yet. Share an insight, caveat, or question.
Greene et al. (2019) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=2,588). Guideline-directed medical therapy (ACEI/ARB, ARNI, beta-blocker, MRA) was evaluated on Longitudinal titration of HFrEF medical therapy (initiation/dosing increase or discontinuation/dosing decrease) at 12 months. Over 12 months of follow-up, less than 1% of eligible HFrEF patients were simultaneously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA, with few patients having doses increased over time.
Synapse has enriched 10 related papers. Consider them for comparative context: